{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:02:14Z","timestamp":1784613734620,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"45","license":[{"start":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T00:00:00Z","timestamp":1530835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009828","name":"Cancer Research Wales (Ymchwil Canser Cymru)","doi-asserted-by":"publisher","award":["508502"],"award-info":[{"award-number":["508502"]}],"id":[{"id":"10.13039\/100009828","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009828","name":"Cancer Research Wales (Ymchwil Canser Cymru)","doi-asserted-by":"publisher","award":["508502"],"award-info":[{"award-number":["508502"]}],"id":[{"id":"10.13039\/100009828","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009828","name":"Cancer Research Wales (Ymchwil Canser Cymru)","doi-asserted-by":"publisher","award":["508502"],"award-info":[{"award-number":["508502"]}],"id":[{"id":"10.13039\/100009828","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000311","name":"Tuberous Sclerosis Association (TSA)","doi-asserted-by":"publisher","award":["2013-P05"],"award-info":[{"award-number":["2013-P05"]}],"id":[{"id":"10.13039\/501100000311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000311","name":"Tuberous Sclerosis Association (TSA)","doi-asserted-by":"publisher","award":["2013-F03"],"award-info":[{"award-number":["2013-F03"]}],"id":[{"id":"10.13039\/501100000311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000311","name":"Tuberous Sclerosis Association (TSA)","doi-asserted-by":"publisher","award":["2015-S01"],"award-info":[{"award-number":["2015-S01"]}],"id":[{"id":"10.13039\/501100000311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000311","name":"Tuberous Sclerosis Association (TSA)","doi-asserted-by":"publisher","award":["2013-P05"],"award-info":[{"award-number":["2013-P05"]}],"id":[{"id":"10.13039\/501100000311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000311","name":"Tuberous Sclerosis Association (TSA)","doi-asserted-by":"publisher","award":["2015-S01"],"award-info":[{"award-number":["2015-S01"]}],"id":[{"id":"10.13039\/501100000311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001771","name":"Tuberous Sclerosis Alliance (TS Alliance)","doi-asserted-by":"publisher","award":["03-15"],"award-info":[{"award-number":["03-15"]}],"id":[{"id":"10.13039\/100001771","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health and Care Research Wales (grant reference number: CA05)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1038\/s41388-018-0381-2","type":"journal-article","created":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T13:51:27Z","timestamp":1530885087000},"page":"5913-5925","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir\u2212bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death"],"prefix":"10.1038","volume":"37","author":[{"given":"Charlotte E.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine A.","family":"Dunlop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Seifan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry D.","family":"McCann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8704-7906","authenticated-orcid":false,"given":"Geraint J.","family":"Parfitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley T.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming H.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian R.","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel J.","family":"Errington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Mark","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Tee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,6]]},"reference":[{"key":"381_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccr.2014.03.015","volume":"25","author":"HJ Clarke","year":"2014","unstructured":"Clarke HJ, Chambers JE, Liniker E, Marciniak SJ. Endoplasmic reticulum stress in malignancy. Cancer Cell. 2014;25:563\u201373.","journal-title":"Cancer Cell"},{"key":"381_CR2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.tcb.2012.02.006","volume":"22","author":"C Appenzeller-Herzog","year":"2012","unstructured":"Appenzeller-Herzog C, Hall MN. Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling. Trends Cell Biol. 2012;22:274\u201382.","journal-title":"Trends Cell Biol"},{"key":"381_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.semcdb.2014.08.006","volume":"36","author":"EA Dunlop","year":"2014","unstructured":"Dunlop EA, Tee AR. mTOR and autophagy: a dynamic relationship governed by nutrients and energy. Semin Cell Dev Biol. 2014;36:121\u20139.","journal-title":"Semin Cell Dev Biol"},{"key":"381_CR4","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1016\/j.bbamcr.2017.07.008","volume":"1864","author":"S Stengel","year":"2017","unstructured":"Stengel S, Messner B, Falk-Paulsen M, Sommer N, Rosenstiel P. Regulated proteolysis as an element of ER stress and autophagy: implications for intestinal inflammation. Biochim Biophys Acta. 2017;1864:2183\u201390.","journal-title":"Biochim Biophys Acta"},{"key":"381_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/path.4827","volume":"241","author":"HC Lam","year":"2017","unstructured":"Lam HC, Nijmeh J, Henske EP. New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex. J Pathol. 2017;241:219\u201325.","journal-title":"J Pathol"},{"key":"381_CR6","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/nature13492","volume":"513","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Nicholatos J, Dreier JR, Ricoult SJ, Widenmaier SB, Hotamisligil GS, et al. Coordinated regulation of protein synthesis and degradation by mTORC1. Nature. 2014;513:440\u20133.","journal-title":"Nature"},{"key":"381_CR7","doi-asserted-by":"publisher","first-page":"F831","DOI":"10.1152\/ajprenal.00441.2011","volume":"303","author":"BJ Siroky","year":"2012","unstructured":"Siroky BJ, Yin H, Babcock JT, Lu L, Hellmann AR, Dixon BP, et al. Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress. Am J Physiol Ren Physiol. 2012;303:F831\u2013844.","journal-title":"Am J Physiol Ren Physiol"},{"key":"381_CR8","doi-asserted-by":"publisher","first-page":"15687","DOI":"10.1074\/jbc.M112.431056","volume":"288","author":"JT Babcock","year":"2013","unstructured":"Babcock JT, Nguyen HB, He Y, Hendricks JW, Wek RC, Quilliam LA. Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response. J Biol Chem. 2013;288:15687\u201398.","journal-title":"J Biol Chem"},{"key":"381_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031900","volume":"7","author":"N Auricchio","year":"2012","unstructured":"Auricchio N, Malinowska I, Shaw R, Manning BD, Kwiatkowski DJ. Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC). PLoS ONE 2012;7:e31900.","journal-title":"PLoS ONE"},{"key":"381_CR10","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1158\/1078-0432.CCR-07-0161","volume":"13","author":"JJ Gills","year":"2007","unstructured":"Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res. 2007;13:5183\u201394.","journal-title":"Clin Cancer Res"},{"key":"381_CR11","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3324\/haematol.2015.135780","volume":"101","author":"C Driessen","year":"2016","unstructured":"Driessen C, Kraus M, Joerger M, Rosing H, Bader J, Hitz F, et al. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65\/08). Haematologica. 2016;101:346\u201355.","journal-title":"Haematologica"},{"key":"381_CR12","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1093\/jnci\/djs396","volume":"104","author":"JS Shim","year":"2012","unstructured":"Shim JS, Rao R, Beebe K, Neckers L, Han I, Nahta R, et al. Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir. J Natl Cancer Inst. 2012;104:1576\u201390.","journal-title":"J Natl Cancer Inst"},{"key":"381_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.leukres.2013.12.017","volume":"38","author":"M Kraus","year":"2014","unstructured":"Kraus M, M\u00fcller-Ide H, R\u00fcckrich T, Bader J, Overkleeft H, Driessen C. Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations. Leuk Res. 2014;38:383\u201392.","journal-title":"Leuk Res"},{"key":"381_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.87","volume":"3","author":"S Kawabata","year":"2012","unstructured":"Kawabata S, Gills JJ, Mercado-Matos JR, Lopiccolo J, Wilson W 3rd, Hollander MC, et al. Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. Cell Death Dis. 2012;3:e353.","journal-title":"Cell Death Dis"},{"key":"381_CR15","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.molonc.2014.11.005","volume":"9","author":"CE Johnson","year":"2015","unstructured":"Johnson CE, Hunt DK, Wiltshire M, Herbert TP, Sampson JR, Errington RJ, et al. Endoplasmic reticulum stress and cell death in mTORC1-overactive cells is induced by nelfinavir and enhanced by chloroquine. Mol Oncol. 2015;9:675\u201388.","journal-title":"Mol Oncol"},{"key":"381_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.2","volume":"3","author":"M Kraus","year":"2013","unstructured":"Kraus M, Bader J, Overkleeft H, Driessen C. Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance. Blood Cancer J. 2013;3:e103.","journal-title":"Blood Cancer J"},{"key":"381_CR17","doi-asserted-by":"publisher","first-page":"8470","DOI":"10.1038\/sj.onc.1205962","volume":"21","author":"A Astrinidis","year":"2002","unstructured":"Astrinidis A, Cash TP, Hunter DS, Walker CL, Chernoff J, Henske EP. Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene. 2002;21:8470\u20136.","journal-title":"Oncogene"},{"key":"381_CR18","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.juro.2014.04.096","volume":"192","author":"ZF Peng","year":"2014","unstructured":"Peng ZF, Yang L, Wang TT, Han P, Liu ZH, Wei Q. Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a systematic review. J Urol. 2014;192:1424\u201330.","journal-title":"J Urol"},{"key":"381_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023379","volume":"6","author":"SL Dabora","year":"2011","unstructured":"Dabora SL, Franz DN, Ashwal S, Sagalowsky A, DiMario FJ Jr, Miles D, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS ONE 2011;6:e23379.","journal-title":"PLoS ONE"},{"key":"381_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/cdd.2010.82","volume":"18","author":"YJ Kang","year":"2011","unstructured":"Kang YJ, Lu MK, Guan KL. The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress-induced apoptosis. Cell Death Differ. 2011;18:133\u201344.","journal-title":"Cell Death Differ"},{"key":"381_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","volume":"36","author":"S Gandolfi","year":"2017","unstructured":"Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastas- Rev. 2017;36:561\u201384.","journal-title":"Cancer Metastas- Rev"},{"key":"381_CR22","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1172\/JCI200317222","volume":"112","author":"H Zhang","year":"2003","unstructured":"Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, Vazquez F, Carpenter CL, Kwiatkowski DJ. Loss of Tsc1\/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest. 2003;112:1223\u201333.","journal-title":"J Clin Invest"},{"key":"381_CR23","doi-asserted-by":"publisher","first-page":"737","DOI":"10.4161\/auto.7.7.15491","volume":"7","author":"EA Dunlop","year":"2011","unstructured":"Dunlop EA, Hunt DK, Acosta-Jaquez HA, Fingar DC, Tee AR. ULK1 inhibits mTORC1 signaling, promotes multisite Raptor phosphorylation and hinders substrate binding. Autophagy. 2011;7:737\u201347.","journal-title":"Autophagy"},{"key":"381_CR24","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1158\/0008-5472.CAN-06-0605","volume":"66","author":"LJ Crawford","year":"2006","unstructured":"Crawford LJ, Walker B, Ovaa H, Chauhan D, Anderson KC, Morris TC, et al. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res. 2006;66:6379\u201386.","journal-title":"Cancer Res"},{"key":"381_CR25","doi-asserted-by":"publisher","first-page":"48711","DOI":"10.18632\/oncotarget.16232","volume":"8","author":"EA Dunlop","year":"2017","unstructured":"Dunlop EA, Johnson CE, Wiltshire M, Errington RJ, Tee AR. Targeting protein homeostasis with nelfinavir\/salinomycin dual therapy effectively induces death of mTORC1 hyperactive cells. Oncotarget. 2017;8:48711\u201324.","journal-title":"Oncotarget"},{"key":"381_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"381_CR27","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1038\/sj.onc.1203622","volume":"19","author":"AR Tee","year":"2000","unstructured":"Tee AR, Proud CG. DNA-damaging agents cause inactivation of translational regulators linked to mTOR signalling. Oncogene. 2000;19:3021\u201331.","journal-title":"Oncogene"}],"updated-by":[{"DOI":"10.1038\/s41388-018-0598-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T00:00:00Z","timestamp":1546905600000}}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0381-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0381-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0381-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:12:37Z","timestamp":1684617157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-018-0381-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,6]]},"references-count":27,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["381"],"URL":"https:\/\/doi.org\/10.1038\/s41388-018-0381-2","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41388-018-0598-0","asserted-by":"object"}]},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,6]]},"assertion":[{"value":"10 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RJE is non-executive director of Biostatus Ltd, the vendor of DRAQ7. The remaining authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}